- Home
- BMM vs KROS Comparison
BMM vs KROS Comparison
Compare BMM & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMM | KROS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | Canada | United States |
| Employees | 27 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 654.0M | 584.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | BMM | KROS |
|---|---|---|
| Price | $8.15 | $11.58 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 100.2K | ★ 362.2K |
| Earning Date | 04-17-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | ★ N/A | $5.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $10.42 |
| 52 Week High | $8.63 | $22.55 |
Technical Indicators
Market Signals| Indicator | BMM | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 66.74 | 42.75 |
| Support Level | $3.49 | $10.56 |
| Resistance Level | $8.63 | $12.65 |
| Average True Range (ATR) | 0.60 | 0.51 |
| MACD | 0.05 | 0.12 |
| Stochastic Oscillator | 82.17 | 34.28 |
Price Performance
Historical ComparisonAbout BMM Blue Moon Metals Inc. Common Shares
Blue Moon Metals Inc is a Canadian exploration stage company which is focused on the exploration and development of mineral resource properties. The company is advancing its Blue Moon polymetallic deposit which contains zinc, gold, silver, and copper. The company also holds the Yava polymetallic project in Nunavut that is in the same volcanic lithologies and south of Glencore's Hackett River deposit. The company is focusing on advancing the Blue Moon and Yava properties.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.